Drug
Akt/ERK Inhibitor ONC201
Akt/ERK Inhibitor ONC201 is a pharmaceutical drug with 5 clinical trials. Currently 2 active trials ongoing.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Completion Rate
0%(0/2)
Active Trials
2(40%)
Terminated
2(40%)
Phase Distribution
Ph phase_2
2
40%
Ph phase_1
3
60%
Phase Distribution
3
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
3(60.0%)
Phase 2Efficacy & side effects
2(40.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 3 finished
Non-Completion Rate
100.0%
3 ended early
Currently Active
2
trials recruiting
Total Trials
5
all time
Status Distribution
Active(2)
Terminated(3)
Detailed Status
Recruiting2
Terminated2
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
2
Success Rate
0.0%
Most Advanced
Phase 2
Trials by Phase
Phase 13 (60.0%)
Phase 22 (40.0%)
Trials by Status
withdrawn120%
recruiting240%
terminated240%
Recent Activity
2 active trials
Showing 5 of 5
recruitingphase_1
ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome
NCT02392572
recruitingphase_2
ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer
NCT04055649
terminatedphase_1
Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT02420795
terminatedphase_2
ONC201 With a Methionine-Restricted Diet in Patients With Metastatic Triple Negative Breast Cancer
NCT03733119
withdrawnphase_1
ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma
NCT04854044
Clinical Trials (5)
Showing 5 of 5 trials
NCT02392572Phase 1
ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome
NCT04055649Phase 2
ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer
NCT02420795Phase 1
Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT03733119Phase 2
ONC201 With a Methionine-Restricted Diet in Patients With Metastatic Triple Negative Breast Cancer
NCT04854044Phase 1
ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5